These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34919831)

  • 1. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia.
    Dabira ED; Soumare HM; Conteh B; Ceesay F; Ndiath MO; Bradley J; Mohammed N; Kandeh B; Smit MR; Slater H; Peeters Grietens K; Broekhuizen H; Bousema T; Drakeley C; Lindsay SW; Achan J; D'Alessandro U
    Lancet Infect Dis; 2022 Apr; 22(4):519-528. PubMed ID: 34919831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entomological impact of mass administration of ivermectin and dihydroartemisinin-piperaquine in The Gambia: a cluster-randomized controlled trial.
    Soumare HM; Dabira ED; Camara MM; Jadama L; Gaye PM; Kanteh S; Jawara EA; Njie AK; Sanneh F; Ndiath MO; Lindsay SW; Conteh B; Ceesay S; Mohammed N; Ooko M; Bradley J; Drakeley C; Erhart A; Bousema T; D'Alessandro U
    Parasit Vectors; 2022 Nov; 15(1):435. PubMed ID: 36397132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial.
    Smit MR; Ochomo EO; Aljayyoussi G; Kwambai TK; Abong'o BO; Chen T; Bousema T; Slater HC; Waterhouse D; Bayoh NM; Gimnig JE; Samuels AM; Desai MR; Phillips-Howard PA; Kariuki SK; Wang D; Ward SA; Ter Kuile FO
    Lancet Infect Dis; 2018 Jun; 18(6):615-626. PubMed ID: 29602751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
    Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
    McLean ARD; Indrasuta C; Khant ZS; Phyo AK; Maung SM; Heaton J; Aung H; Aung Y; Soe K; Swe MMM; von Seidlein L; Tun NN; Tun KM; Day NPJ; Ashley EA; Hlaing T; Kyaw TT; Dondorp AM; Imwong M; White NJ; Smithuis FM
    Lancet Infect Dis; 2021 Nov; 21(11):1579-1589. PubMed ID: 34147154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
    Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
    Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent
    Stone W; Mahamar A; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Youssouf A; Diallo M; Soumare HM; Kaur H; Lanke K; Ter Heine R; Bradley J; Issiaka D; Diawara H; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 Jan; 3(1):e41-e51. PubMed ID: 35028628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study.
    Slater HC; Foy BD; Kobylinski K; Chaccour C; Watson OJ; Hellewell J; Aljayyoussi G; Bousema T; Burrows J; D'Alessandro U; Alout H; Ter Kuile FO; Walker PGT; Ghani AC; Smit MR
    Lancet Infect Dis; 2020 Apr; 20(4):498-508. PubMed ID: 31948767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
    Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
    Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial.
    van der Pluijm RW; Tripura R; Hoglund RM; Pyae Phyo A; Lek D; Ul Islam A; Anvikar AR; Satpathi P; Satpathi S; Behera PK; Tripura A; Baidya S; Onyamboko M; Chau NH; Sovann Y; Suon S; Sreng S; Mao S; Oun S; Yen S; Amaratunga C; Chutasmit K; Saelow C; Runcharern R; Kaewmok W; Hoa NT; Thanh NV; Hanboonkunupakarn B; Callery JJ; Mohanty AK; Heaton J; Thant M; Gantait K; Ghosh T; Amato R; Pearson RD; Jacob CG; Gonçalves S; Mukaka M; Waithira N; Woodrow CJ; Grobusch MP; van Vugt M; Fairhurst RM; Cheah PY; Peto TJ; von Seidlein L; Dhorda M; Maude RJ; Winterberg M; Thuy-Nhien NT; Kwiatkowski DP; Imwong M; Jittamala P; Lin K; Hlaing TM; Chotivanich K; Huy R; Fanello C; Ashley E; Mayxay M; Newton PN; Hien TT; Valecha N; Smithuis F; Pukrittayakamee S; Faiz A; Miotto O; Tarning J; Day NPJ; White NJ; Dondorp AM;
    Lancet; 2020 Apr; 395(10233):1345-1360. PubMed ID: 32171078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive, self-administered malaria treatment against asymptomatic malaria infection: results of a cluster randomized controlled trial in The Gambia.
    Okebe J; Dabira E; Jaiteh F; Mohammed N; Bradley J; Drammeh NF; Bah A; Masunaga Y; Achan J; Muela Ribera J; Yeung S; Balen J; Peeters Grietens K; D'Alessandro U
    Malar J; 2021 Jun; 20(1):253. PubMed ID: 34098984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.
    Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Pace C; Lukito T; Maratina SS; Asih PBS; Santana-Morales MA; Adams ER; Unwin VT; Williams CT; Chen T; Smedley J; Wang D; Faragher B; Price RN; Ter Kuile FO
    Lancet Infect Dis; 2019 Sep; 19(9):973-987. PubMed ID: 31353217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial.
    Dabira ED; Soumare HM; Lindsay SW; Conteh B; Ceesay F; Bradley J; Kositz C; Broekhuizen H; Kandeh B; Fehr AE; Nieto-Sanchez C; Ribera JM; Peeters Grietens K; Smit MR; Drakeley C; Bousema T; Achan J; D'Alessandro U
    JMIR Res Protoc; 2020 Nov; 9(11):e20904. PubMed ID: 33211022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting-high coverage and safety, but no significant impact on transmission.
    Morris U; Msellem MI; Mkali H; Islam A; Aydin-Schmidt B; Jovel I; Shija SJ; Khamis M; Ali SM; Hodzic L; Magnusson E; Poirot E; Bennett A; Sachs MC; Tarning J; Mårtensson A; Ali AS; Björkman A
    BMC Med; 2018 Dec; 16(1):215. PubMed ID: 30526588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
    Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
    Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass Drug Administration With Dihydroartemisinin-piperaquine and Malaria Transmission Dynamics in The Gambia: A Prospective Cohort Study.
    Mwesigwa J; Achan J; Affara M; Wathuo M; Worwui A; Mohammed NI; Kanuteh F; Prom A; Dierickx S; di Tanna GL; Nwakanma D; Bousema T; Drakeley C; Van Geertruyden JP; D'Alessandro U
    Clin Infect Dis; 2019 Jul; 69(2):278-286. PubMed ID: 30304511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial.
    Hamaluba M; van der Pluijm RW; Weya J; Njuguna P; Ngama M; Kalume P; Mwambingu G; Ngetsa C; Wambua J; Boga M; Mturi N; Lal AA; Khuroo A; Taylor WRJ; Gonçalves S; Miotto O; Dhorda M; Mutinda B; Mukaka M; Waithira N; Hoglund RM; Imwong M; Tarning J; Day NPJ; White NJ; Bejon P; Dondorp AM
    Lancet Infect Dis; 2021 Oct; 21(10):1395-1406. PubMed ID: 34111412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia.
    Fehr A; Nieto-Sanchez C; Muela J; Jaiteh F; Ceesay O; Maneh E; Baldeh D; Achan J; Dabira E; Conteh B; Bunders-Aelen J; Smekens T; Broekhuizen H; D'Alessandro U; Peeters Grietens K
    Malar J; 2021 Apr; 20(1):198. PubMed ID: 33902611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
    Dicko A; Brown JM; Diawara H; Baber I; Mahamar A; Soumare HM; Sanogo K; Koita F; Keita S; Traore SF; Chen I; Poirot E; Hwang J; McCulloch C; Lanke K; Pett H; Niemi M; Nosten F; Bousema T; Gosling R
    Lancet Infect Dis; 2016 Jun; 16(6):674-684. PubMed ID: 26906747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.